Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Genetics of leukaemia relapse revealed

01 December 2008

By Dr Charlotte Maden

Appeared in BioNews 486

Scientists have uncovered key genetic changes in the cancer-causing cells when childhood leukaemia recurs. It is hoped that the findings can be used to help beat the disease.

Acute lymphoblastic leukaemia (ALL), a cancer of the blood and bone marrow, is the most common form of childhood cancer. Eighty per cent of children with the disease are cured, but of those that suffer a relapse, only 30 per cent survive.

In their study, researchers at the St Jude Children's Research Hospital in Memphis, Tennessee, US, analysed the genes in the cancer cells of 61 children with ALL when they were initially diagnosed, and then compared them to the genes after they relapsed. By examining copy-number variations (lengths of DNA that are lost or duplicated) they found that only six per cent of relapses were caused by new cancers. In 42 per cent of patients, cells causing the relapse were direct descendents of the cancer cells identified at initial diagnosis. In 52 per cent, however, the relapse was caused by ancestors of the original cancer cells that were not detected when the patients were initially screened.

The work, published in Science, reports that the genetic changes were found to affect the biological machinery of B cells (white blood cells) as well as tumour suppression genes, but were rarely found to affect the genes controlling response to treatments.

'The key finding', explains Dr James Downing, one of the study's authors, 'is that in the majority of cases, relapse is arising from a cell already present at time of diagnosis. That cell is selected for during treatment and then subsequently emerges as a basis for relapse'.

The hope is to create more sensitive detection techniques to pick up the variants of the cancer cells, and create drugs that interrupt the changed genetic pathways, thereby disrupting the process of relapse. 'You've got to get them at the time of diagnosis, you can't wait till the patient relapses', said Dr Charles Mullighan, the co-author.

Mel Greaves works on ALL at the Institute of Cancer Research in London. He describes the work as 'elegant' and the clearest picture of relapse yet, but says that 'the clinical relevance of the biology is up in the air' due to the study missing out important clinical data. Downing says that there is further data to be published in the New England Journal of Medicine that will help doctors predict whether a particular patient's treatment will be successful.

SOURCES & REFERENCES
Nature | 27 November 2008
 
Reuters | 27 November 2008
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

04 April 2011 - by Maren Urner 
Researchers from the Wellcome Trust Sanger Institute have identified three different genetic mutations linked to acute myeloid leukaemia (AML), a cancer that is characterised by a rapid increase in abnormal white blood cells in the bone marrow....
12 January 2009 - by Dr Charlotte Maden 
A new report published online in the New England Journal of Medicine last week describes the clinical relevance of the genetic changes in children with acute lymphoblastic leukaemia (ALL). ALL, a cancer of the blood and bone marrow, is the most prevalent cancer in children. The cure...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation